News & Articles

Vascular Specialty Center a Leading Center for Kidney Protection Trial

Baton Rouge, LA - Vascular Specialty Center is the nation’s leading vascular surgical enroller for the national trial: Targeted Intra-renal Fenoldopam for Avoidance of Nephropathy (TIFFANY) Study: Renal Contrast Nephropathy Incidence in High Risk Patients. 

This is a randomized, placebo-controlled physician-sponsored U.S. clinical study evaluating treatment with intra-renal (IR) fenoldopam using the Benephit Infusion System in patients at very high risk for RCN, diabetics with moderate or severe renal dysfunction. This study will assess whether the administration of fenoldopam during angiography protects the kidney from damage that may be cause by contrast dye in those at risk.

“As more of our procedures become endovascular and thus angiogram based, we are committed to ensuring that we obtain maximal kidney protection to avoid the onset of renal failure”, says Dr. Albert Sam. 

About Vascular Specialty Center, PMC

Vascular Specialty Center is the largest single specialty vascular and endovascular surgical practice in the gulf coast region with headquarters in Baton Rouge, LA. Its subsidiaries include Vascular Specialty Center’ Laboratory (VSL) and Total Vein Care of Louisiana TM (TVC). VSL serves as the largest vascular laboratory in the state and serves the entire Gulf Coast region performing more than 12,000 non-invasive studies yearly. TVC is the leading freestanding gulf coast clinic dedicated to the complete medical, surgical and cosmetic care of problematic veins performing more minimally invasive, endoluminal vein ablations than any center in the Southeastern United States.

www.brvsc.com
www.TotalVeinCareLouisiana.com